February 21, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024.
Philips’ Annual Report 2024 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2025. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.
Philips filed the Annual Report 2024 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).
The Annual Report 2024 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.
For further information, please contact:
Elco van Groningen
Philips Global External Relations
Tel.: +31 68103 9584
E-mail: elco.van.groningen@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18.0 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
-
Philips publishes its Annual Report 2024February 21, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its A2025-02-24
-
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustek2025-02-24
-
聚焦热门话题,150+采购团,BTE 2025助企高效对接当全球生物医药产业迎来第三次技术革命浪潮,一场汇聚全球顶尖智慧的生物技术行业盛会即将启幕。由蛋白药研究会、广东省生物产业协会、广州医药行业协会、振威国2025-02-24
-
糖立康创始人向梅英:科技赋能,开启糖尿病管理新篇章在全球公共卫生领域,糖尿病如同一道沉重的阴影,悄然威胁着无数人的健康。据国际糖尿病联盟的最新数据,我国成人糖尿病患病率已攀升至11.6%,更令人担忧的是,患者群体正2025-02-24
-
PCHi2025圆满成功!博溪检测科技创新领航化妆品CRO服务未来2月19日-21日,全球化妆品行业瞩目盛会中国国际化妆品个人及家庭护理用品原料展览会(PCHi2025)在中国进出口商品交易会展馆盛大举行。作为国内体外科学与精准测评领导2025-02-24